Autoimmune Blistering Diseases Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Gender/Age: Males or females above 18 years old
Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid
Subjects able to give informed consent
Disqualifiers
Patients who are under age 18 years.
Patients without pemphigus or pemphigoid diseases
Penn employees
Penn students
Trial population
Adult patients over the age of 18 who have been diagnosed with pemphigus vulgaris, pemphigus foliaceus or bullous pemphigoid.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Questionnaires
Other intervention
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Pemphigus Disease Area Index (PDAI)
Time frame
one year2
Bullous Pemphigoid Disease Area Index (BPDAI)
Time frame
one yearSecondary outcomes
1
Autoimmune Bullous Disease Quality of Life (ABQOL)
Time frame
one year2
Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL)
Time frame
one year3
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS)
Time frame
one yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov